Barinthus Biotherapeutics Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.2%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.90next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Restricted Cash Quarterly67.2MTarget: Sufficient to fund standalone operations for at least 12 months
Quarterly Net Loss Attributable to Shareholders Quarterly-5.5MTarget: Narrowing loss through portfolio refocusing and cost management
Quarterly Research and Development (R&D) Expenses Quarterly3.6MTarget: Disciplined spend focused on prioritized autoimmune programs
Watch Items
- Completion of the proposed all-stock merger with Clywedog TherapeuticsTrigger: Closing of the transaction (originally targeted for Q2 2026)Action: Transition listing to NASDAQ under the new ticker symbol 'CLYD' and rename the combined entity to Clywedog Therapeutics Holdings, Inc.
- Phase 1 AVALON clinical trial of lead asset VTP-1000 in celiac diseaseTrigger: Release of multiple ascending dose (MAD) dataAction: Evaluate safety, tolerability, and pharmacodynamic markers (including gluten challenge) in the second half of 2026 to confirm disease-modifying potential.
- Phase 2a clinical trials of Clywedog's metabolic assets (CLY-101 and CLY-201)Trigger: First top-line data readouts for Type 1 and Type 2 diabetesAction: Review clinical proof-of-concept data expected in the second half of 2026 to validate the expanded metabolic pipeline.
Research as of 20 Jun 2026